WallStreetZenWallStreetZen

NASDAQ: NARI
Inari Medical Inc Stock

$46.30-0.69 (-1.47%)
Updated May 16, 2024
NARI Price
$46.30
Fair Value Price
-$37.03
Market Cap
$2.69B
52 Week Low
$36.73
52 Week High
$71.85
P/E
-115.75x
P/B
6.02x
P/S
5.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$520.66M
Earnings
-$23.62M
Gross Margin
87.7%
Operating Margin
-2%
Profit Margin
-4.5%
Debt to Equity
0.48
Operating Cash Flow
$26M
Beta
1.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NARI Overview

Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NARI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NARI ($46.30) is overvalued by 225.02% relative to our estimate of its Fair Value price of -$37.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NARI ($46.30) is not significantly undervalued (225.02%) relative to our estimate of its Fair Value price of -$37.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NARI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NARI due diligence checks available for Premium users.

Be the first to know about important NARI news, forecast changes, insider trades & much more!

NARI News

Valuation

NARI fair value

Fair Value of NARI stock based on Discounted Cash Flow (DCF)
Price
$46.30
Fair Value
-$37.03
Undervalued by
225.02%
NARI ($46.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NARI ($46.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NARI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NARI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-115.75x
Industry
30.63x
Market
31.03x

NARI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.02x
Industry
4x
NARI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NARI's financial health

Profit margin

Revenue
$143.2M
Net Income
-$24.2M
Profit Margin
-16.9%
NARI's Earnings (EBIT) of -$10.41M... subscribe to Premium to read more.
Interest Coverage Financials
NARI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$661.8M
Liabilities
$214.5M
Debt to equity
0.48
NARI's short-term assets ($233.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NARI's short-term assets ($233.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NARI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$12.3M
Investing
$39.2M
Financing
$1.0M
NARI's operating cash flow ($25.65M)... subscribe to Premium to read more.
Debt Coverage Financials

NARI vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
NARI$2.69B-1.47%-115.75x6.02x
QDEL$2.95B-2.16%-1.67x0.89x
NVCR$2.39B+5.32%-12.32x6.64x
TNDM$3.03B-0.93%-21.63x12.47x
CNMD$2.33B+1.29%28.07x2.72x

Inari Medical Stock FAQ

What is Inari Medical's quote symbol?

(NASDAQ: NARI) Inari Medical trades on the NASDAQ under the ticker symbol NARI. Inari Medical stock quotes can also be displayed as NASDAQ: NARI.

If you're new to stock investing, here's how to buy Inari Medical stock.

What is the 52 week high and low for Inari Medical (NASDAQ: NARI)?

(NASDAQ: NARI) Inari Medical's 52-week high was $71.85, and its 52-week low was $36.73. It is currently -35.56% from its 52-week high and 26.05% from its 52-week low.

How much is Inari Medical stock worth today?

(NASDAQ: NARI) Inari Medical currently has 58,138,159 outstanding shares. With Inari Medical stock trading at $46.30 per share, the total value of Inari Medical stock (market capitalization) is $2.69B.

Inari Medical stock was originally listed at a price of $42.51 in May 22, 2020. If you had invested in Inari Medical stock at $42.51, your return over the last 3 years would have been 8.92%, for an annualized return of 2.89% (not including any dividends or dividend reinvestments).

How much is Inari Medical's stock price per share?

(NASDAQ: NARI) Inari Medical stock price per share is $46.30 today (as of May 16, 2024).

What is Inari Medical's Market Cap?

(NASDAQ: NARI) Inari Medical's market cap is $2.69B, as of May 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Inari Medical's market cap is calculated by multiplying NARI's current stock price of $46.30 by NARI's total outstanding shares of 58,138,159.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.